Epidermal growth factor receptor-directed therapy in esophageal cancer

Oncology

Volumn 73, Issue 5-6, 2008, Pages 281-289

  Pande, A U ^a   Iyer, R V ^a   Rani, A ^b   Maddipatla, S ^b   Yang, G Y ^a   Nwogu, C E ^a   Black, J D ^a   Levea, C M ^a   Javle, M M ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Barrett's esophagus; Epidermal growth factor receptor; Esophageal neoplasms

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIGALLOCATECHIN GALLATE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VANDETANIB;

ANTINEOPLASTIC ACTIVITY; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RASH; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVIEW; SKIN TOXICITY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; HUMANS; INCIDENCE; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 45549103190     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000132393     Document Type: Review

References (57)

1. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26(suppl 15):2-8.
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289.
3. Eksteen JA, Jankowski JA: Surveillance for Barrett's esophagus. The conundrum of Barrett's esophagus is changing. BMJ 2001;322:1124-1125.
4. Nishigaki H, Wada K, Tatsuguchi A, et al: ErbB2 without erbB3 expression in metaplastic columnar epithelium of Barrett's esophagus. Digestion 2004;70:95-102.
5. Jankowski J, Hopwood D, Pringle R, Wormsley KG: Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis. Am J Gastroenterol 1993;88:402-408.
6. Jaiswal K, Lopez-Guzman C, Souza RF, Spechler SJ, Sarosi GA Jr: Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol 2006;290:G335-G342.
7. Sarosi GA Jr, Jaiswal K, Herndon E, Lopez-Guzman C, Spechler SJ, Souza RF: Acid increases MAPK-mediated proliferation in Barrett's esophageal adenocarcinoma cells via intracellular acidification through a Cl-/HCO3- exchanger. Am J Physiol Gastrointest Liver Physiol 2005;289:G991-G997.
8. Souza RF, Shewmake KL, Shen Y, et al: Differences in ERK activation in squamous mucosa in patients who have gastroesophageal reflux disease with and without Barrett's esophagus. Am J Gastroenterol 2005;100:551-559.
9. Harris JC, Clarke PA, Awan A, Jankowski J, Watson SA: An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 2004;64:1915-1919.
10. Vona-Davis L, Frankenberry K, Cunningham C, et al: MAPK and PI3K inhibition reduces proliferation of Barrett's adenocarcinoma in vitro. J Surg Res 2005;127:53-58.
11. Rani A, Javle M, LeVea C, Yu J, Brattain M, Black J, Sitrin M: EGFR, p-Erk and p-AKT expression in Barrett's esophagus (BE): a prospective pilot study. Am J Gastroenterol 2007;102:S119-S156.
12. al-Kasspooles M, Moore JH, Orringer MB, Beer DG: Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993;54:213-219.
13. Lu SH, Hsieh LL, Luo FC, Weinstein IB: Amplification of the EGF receptor and c-myc genes in human esophageal cancers. Int J Cancer 1988;42:502-505.
14. Watanabe G, Kaganoi J, Imamura M, et al: Progression of esophageal carcinoma by loss of EGF-STAT1 pathway. Cancer J 2001;7:132-139.
15. Jankowski J, Murphy S, Coghill G, et al: Epidermal growth factor receptors in the oesophagus. Gut 1992;33:439-443.
16. Jankowski J: Altered gene expression of growth factors and their receptors during esophageal tumorigenesis. Gastroenterol Clin Biol 1994;18:D40-D45.
17. Schrump DS, Nguyen DM: The epidermal growth factor receptor-STAT pathway in esophageal cancer. Cancer J 2001;7:108-111.
18. Wilkinson NW, Black JD, Roukhadze E, et al: Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 2004;8:448-453.
19. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ: Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767-5772.
20. Tew WP, Kelsen DP, Ilson DH: Targeted therapies for esophageal cancer. Oncologist 2005;10:590-601.
21. Tabernero J, Macarulla T, Ramos FJ, Baselga J: Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 2005;16:1740-1748.
22. Vanhoefer U, Tewes M, Rojo F, et al: Phase I study of the humanized anti-epidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004;22:175-184.
23. Hecht J, Patnaik A, Malik I, Venook A, Berlin J, Croghan G, Wiens B, Visonneau S, Jerian S, Meropol N: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. J Clin Oncol 2004;22:3511.
24. Figlin R, Belldegrun A, Lohner M, Roskos L, Yang X, Schwab G, Weiner L: ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002;21(suppl 10):35.
25. Dobelbower MC, Russo SM, Raisch KP, Seay LL, Clemons LK, Suter S, Posey J, Bonner JA: Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs 2006;17:95-102.
26. Guo M, Liu S, Lu F: Gefitinib-sensitizing mutations in esophageal carcinoma. N Engl J Med;354:2193-2194.
27. Sutter AP, Huether A, Maaser K, Scherubl H: Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer 2006;118:1114-1127.
28. Tew WP, Shah M, Schwartz G, Kelsen D, Ilson H: Phase II trial of erlotinib for secondline treatment in advanced esophageal cancer. Proc Am Soc Clin Oncol Gastrointest Cancer Symp 2005;23:5a.
29. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C, Giaccone G: Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24:1612-1619.
30. Ferry D, Anderson M, Beddows K, Mayer P, Price L, Jankowski J: Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. J Clin Oncol 2004;22:4021.
31. Hou Z, Sang S, You H, Lee MJ, Hong J, Chin KV, Yang CS: Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res 2005;65:8049-8056.
32. Park SY, Seol DW: Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 2002;295:515-518.
33. Teraishi F, Kagawa S, Watanabe T, Tango Y, Kawashima T, Umeoka T, Nisizaki M, Tanaka N, Fujiwara T: ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptortyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett 2005;579:4069-4075.
34. Lippman SM, Gibson N, Subbaramaiah K, Dannenberg AJ: Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res 2005;11:6097-6099.
35. Vervenne W, Bollen J, Bergman J, Nio C, Hulshof M, Van Lanschot J, Richel D: Evaluation of the antitumor activity of gefitinib (ZD1839) in combination with celecoxib in patients with advanced esophageal cancer. J Clin Oncol 2004;22:4054.
36. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970.
37. Delord J, Beale P, Van Cutsem E, Clarke S, Verslype C, Bugat R, Rakhit A, Fettner S, Brennscheidt U, Feyereislova A: A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients. J Clin Oncol 2004;22:3585.
38. Messersmith WA: Phase I trial and biologic study of erlotinib combined with folfox-4 in patients with advanced colorectal cancer: initial results. Proc Am Soc Clin Oncol Gastrointest Cancer Symp, Hollywood, 2005, p 260a.
39. Meyerhardt J, Xhu A, Enzinger P, Ryan D, Clark J, Kulke M, Michelini M, Vincitore M, Thomas A, Fuchs C: Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). J Clin Oncol 2004;22:3580.
40. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aranda Aguilar E, Aapro M, Van Den Berg N, Eggleton S, Siena S: MABEL - a large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. J Clin Oncol; 2006;24:3549.
41. Bonner J, Giralt J, Harari P, Cohen R, Jones C, Sur R, Rabin D, Azarnia N, Needle M, Ang K: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 2004;22:5507.
42. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. PNAS 2004;101:13306-13311.
43. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA Jr: Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007;18:752-760.
44. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006;12:4283-4287.
45. Suntharalingam M, Dipetrillo T, Akerman P, Wanebo H, Daly B, Doyle L, Krasna M, Kennedy T, Safran H: Cetuximab, paclitaxel, carboplatin and radiation for esophageal and gastric cancer. J Clin Oncol 2006;24:4029.
46. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe F, Ceccarelli C, Mutri V, Giaquinta S, Piana E, Martoni A: Phase II study of cetuximab in combination with FOLFIRI as firstline treatment in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results. J Clin Oncol 2006;24:4031.
47. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2152-2155.
48. Taira N, Doihara H, Oota T, Hara F, Shien T, Takahashi H, Yoshitomi S, Ishibe Y, Shimizu N: Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro. Acta Med Okayama 2006;60:25-34.
49. Kim DW, Choy H: Potential role for epidermal growth factor receptor inhibitors in combined modality therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59(suppl 2):11-20.
50. Nokihara H, Ohe Y, Kawaishi M, Kato T, Yamamoto N, Sekine I, Kunitoh H, Saijo N, Tamura T: A randomized phase II study of sequential carboplatin/paclitaxel (CP) and gefitinib (G) in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC): preliminary results. J Clin Oncol 2006;24:7096.
51. Pande A, Iyer R, Nava H, Yang G, Nwogu C, Schiff M, LeVea C, Black J, Javle M: Gefitinib (ZD1839) with oxaliplatin and radiotherapy (RT) for esophageal carcinoma (EC). Proc GI ASCO 2007; abstract no. 68.
52. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, et al: Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) 2005;65:3328-3335.
53. Bizari L, Borim AA, Leite KR, Goncalves Fde T, Cury PM, Tajara EH, Silva AE: Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet 2006;165:41-50.
54. Safran H, DiPetrillo T, Nadeem A, Steinhoff M, Tantravahi U, Rathore R, Wanebo H, Hughes M, Maia C, Tsai JY, Pasquariello T, Pepperell JR, Cioffi W, Kennedy T, Reeder L, Ng T, Adrian A, Goldstein L, Chak B, Choy H: Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 2004;22:670-677.
55. Shaukat A, Mortazavi A, Demmy T, Nava H, Wilkinson N, Yang G, Kepner J, Javle M: Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients? Dis Esophagus 2004;17:129-135.
56. Dragovich T, McCoy S, Fenoglio-Preiser C, et al: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2007;25:2334.
57. Van Groeningen C, Richel D, Giaccone G: Gefitinib phase II study in second-line treatment of advanced esophageal cancer. J Clin Oncol 2004;22:4022.